Selected research
Industry Research
Biosimilars of Rituximab Industry Research Report 2026
Market perspective
The global Biosimilars of Rituximab market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Biosimilars of Rituximab is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Biosimilars of Rituximab is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Biosimilars of Rituximab is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Biosimilars of Rituximab include AryoGen Pharmed, Biocad, Cadila Pharmaceuticals, Celltrion, Dr Reddy’s Laboratories, Hetero Group, Innovent Biologics, Intas Biopharmaceuticals and Probiomed, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Biosimilars of Rituximab market in terms of revenue (US$ million) and, where applicable, sales volume (K Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biosimilars of Rituximab Market by Company
AryoGen Pharmed
Biocad
Cadila Pharmaceuticals
Celltrion
Dr Reddy’s Laboratories
Hetero Group
Innovent Biologics
Intas Biopharmaceuticals
Probiomed
TRPharma
Viatris
Zenotech Laboratories
Amgen
Teva
Biosimilars of Rituximab Segment by Type
500mg
100mg
Other
Biosimilars of Rituximab Segment by Application
Hospital Pharmacy
Retail Pharmacy
Biosimilars of Rituximab Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars of Rituximab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilars of Rituximab and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars of Rituximab.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biosimilars of Rituximab manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biosimilars of Rituximab by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biosimilars of Rituximab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 500mg
- 100mg
- Other
Applications
- Hospital Pharmacy
- Retail Pharmacy
Companies covered
- AryoGen Pharmed
- Biocad
- Cadila Pharmaceuticals
- Celltrion
- Dr Reddy’s Laboratories
- Hetero Group
- Innovent Biologics
- Intas Biopharmaceuticals
- Probiomed
- TRPharma
- Viatris
- Zenotech Laboratories
- Amgen
- Teva
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Biosimilars of Rituximab Market Size (2021-2032)
- 2.2.2 Global Biosimilars of Rituximab Sales (2021-2032)
- 2.2.3 Global Biosimilars of Rituximab Market Average Price (2021-2032)
- 2.3 Biosimilars of Rituximab by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 500mg
- 2.3.3 100mg
- 2.3.4 Other
- 2.4 Biosimilars of Rituximab by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacy
- 2.4.3 Retail Pharmacy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Biosimilars of Rituximab Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Biosimilars of Rituximab Sales (K Pcs) of Manufacturers (2021-2026)
- 3.3 Global Biosimilars of Rituximab Revenue of Manufacturers (2021-2026)
- 3.4 Global Biosimilars of Rituximab Average Price by Manufacturers (2021-2026)
- 3.5 Global Biosimilars of Rituximab Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Biosimilars of Rituximab, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Biosimilars of Rituximab, Product Type & Application
- 3.8 Global Manufacturers of Biosimilars of Rituximab, Established Date
- 3.9 Global Biosimilars of Rituximab Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AryoGen Pharmed
- 4.1.1 AryoGen Pharmed Company Information
- 4.1.2 AryoGen Pharmed Business Overview
- 4.1.3 AryoGen Pharmed Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AryoGen Pharmed Biosimilars of Rituximab Product Portfolio
- 4.1.5 AryoGen Pharmed Recent Developments
- 4.2 Biocad
- 4.2.1 Biocad Company Information
- 4.2.2 Biocad Business Overview
- 4.2.3 Biocad Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Biocad Biosimilars of Rituximab Product Portfolio
- 4.2.5 Biocad Recent Developments
- 4.3 Cadila Pharmaceuticals
- 4.3.1 Cadila Pharmaceuticals Company Information
- 4.3.2 Cadila Pharmaceuticals Business Overview
- 4.3.3 Cadila Pharmaceuticals Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Cadila Pharmaceuticals Biosimilars of Rituximab Product Portfolio
- 4.3.5 Cadila Pharmaceuticals Recent Developments
- 4.4 Celltrion
- 4.4.1 Celltrion Company Information
- 4.4.2 Celltrion Business Overview
- 4.4.3 Celltrion Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Celltrion Biosimilars of Rituximab Product Portfolio
- 4.4.5 Celltrion Recent Developments
- 4.5 Dr Reddy’s Laboratories
- 4.5.1 Dr Reddy’s Laboratories Company Information
- 4.5.2 Dr Reddy’s Laboratories Business Overview
- 4.5.3 Dr Reddy’s Laboratories Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Dr Reddy’s Laboratories Biosimilars of Rituximab Product Portfolio
- 4.5.5 Dr Reddy’s Laboratories Recent Developments
- 4.6 Hetero Group
- 4.6.1 Hetero Group Company Information
- 4.6.2 Hetero Group Business Overview
- 4.6.3 Hetero Group Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hetero Group Biosimilars of Rituximab Product Portfolio
- 4.6.5 Hetero Group Recent Developments
- 4.7 Innovent Biologics
- 4.7.1 Innovent Biologics Company Information
- 4.7.2 Innovent Biologics Business Overview
- 4.7.3 Innovent Biologics Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Innovent Biologics Biosimilars of Rituximab Product Portfolio
- 4.7.5 Innovent Biologics Recent Developments
- 4.8 Intas Biopharmaceuticals
- 4.8.1 Intas Biopharmaceuticals Company Information
- 4.8.2 Intas Biopharmaceuticals Business Overview
- 4.8.3 Intas Biopharmaceuticals Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Intas Biopharmaceuticals Biosimilars of Rituximab Product Portfolio
- 4.8.5 Intas Biopharmaceuticals Recent Developments
- 4.9 Probiomed
- 4.9.1 Probiomed Company Information
- 4.9.2 Probiomed Business Overview
- 4.9.3 Probiomed Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Probiomed Biosimilars of Rituximab Product Portfolio
- 4.9.5 Probiomed Recent Developments
- 4.10 TRPharma
- 4.10.1 TRPharma Company Information
- 4.10.2 TRPharma Business Overview
- 4.10.3 TRPharma Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 TRPharma Biosimilars of Rituximab Product Portfolio
- 4.10.5 TRPharma Recent Developments
- 4.11 Viatris
- 4.11.1 Viatris Company Information
- 4.11.2 Viatris Business Overview
- 4.11.3 Viatris Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Viatris Biosimilars of Rituximab Product Portfolio
- 4.11.5 Viatris Recent Developments
- 4.12 Zenotech Laboratories
- 4.12.1 Zenotech Laboratories Company Information
- 4.12.2 Zenotech Laboratories Business Overview
- 4.12.3 Zenotech Laboratories Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Zenotech Laboratories Biosimilars of Rituximab Product Portfolio
- 4.12.5 Zenotech Laboratories Recent Developments
- 4.13 Amgen
- 4.13.1 Amgen Company Information
- 4.13.2 Amgen Business Overview
- 4.13.3 Amgen Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Amgen Biosimilars of Rituximab Product Portfolio
- 4.13.5 Amgen Recent Developments
- 4.14 Teva
- 4.14.1 Teva Company Information
- 4.14.2 Teva Business Overview
- 4.14.3 Teva Biosimilars of Rituximab Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Teva Biosimilars of Rituximab Product Portfolio
- 4.14.5 Teva Recent Developments
5 Global Biosimilars of Rituximab Market Scenario by Region
- 5.1 Global Biosimilars of Rituximab Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Biosimilars of Rituximab Sales by Region: 2021-2032
- 5.2.1 Global Biosimilars of Rituximab Sales by Region: 2021-2026
- 5.2.2 Global Biosimilars of Rituximab Sales by Region: 2027-2032
- 5.3 Global Biosimilars of Rituximab Revenue by Region: 2021-2032
- 5.3.1 Global Biosimilars of Rituximab Revenue by Region: 2021-2026
- 5.3.2 Global Biosimilars of Rituximab Revenue by Region: 2027-2032
- 5.4 North America Biosimilars of Rituximab Market Facts & Figures by Country
- 5.4.1 North America Biosimilars of Rituximab Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Biosimilars of Rituximab Sales by Country (2021-2032)
- 5.4.3 North America Biosimilars of Rituximab Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Biosimilars of Rituximab Market Facts & Figures by Country
- 5.5.1 Europe Biosimilars of Rituximab Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Biosimilars of Rituximab Sales by Country (2021-2032)
- 5.5.3 Europe Biosimilars of Rituximab Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Biosimilars of Rituximab Market Facts & Figures by Country
- 5.6.1 Asia Pacific Biosimilars of Rituximab Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Biosimilars of Rituximab Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Biosimilars of Rituximab Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Biosimilars of Rituximab Market Facts & Figures by Country
- 5.7.1 South America Biosimilars of Rituximab Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Biosimilars of Rituximab Sales by Country (2021-2032)
- 5.7.3 South America Biosimilars of Rituximab Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Biosimilars of Rituximab Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Biosimilars of Rituximab Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Biosimilars of Rituximab Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Biosimilars of Rituximab Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Biosimilars of Rituximab Sales by Type (2021-2032)
- 6.1.1 Global Biosimilars of Rituximab Sales by Type (2021-2032) & (K Pcs)
- 6.1.2 Global Biosimilars of Rituximab Sales Market Share by Type (2021-2032)
- 6.2 Global Biosimilars of Rituximab Revenue by Type (2021-2032)
- 6.2.1 Global Biosimilars of Rituximab Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Biosimilars of Rituximab Revenue Market Share by Type (2021-2032)
- 6.3 Global Biosimilars of Rituximab Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Biosimilars of Rituximab Sales by Application (2021-2032)
- 7.1.1 Global Biosimilars of Rituximab Sales by Application (2021-2032) & (K Pcs)
- 7.1.2 Global Biosimilars of Rituximab Sales Market Share by Application (2021-2032)
- 7.2 Global Biosimilars of Rituximab Revenue by Application (2021-2032)
- 7.2.1 Global Biosimilars of Rituximab Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Biosimilars of Rituximab Revenue Market Share by Application (2021-2032)
- 7.3 Global Biosimilars of Rituximab Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Biosimilars of Rituximab Value Chain Analysis
- 8.1.1 Biosimilars of Rituximab Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Biosimilars of Rituximab Production Mode & Process
- 8.2 Biosimilars of Rituximab Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Biosimilars of Rituximab Distributors
- 8.2.3 Biosimilars of Rituximab Customers
9 Global Biosimilars of Rituximab Analyzing Market Dynamics
- 9.1 Biosimilars of Rituximab Industry Trends
- 9.2 Biosimilars of Rituximab Industry Drivers
- 9.3 Biosimilars of Rituximab Industry Opportunities and Challenges
- 9.4 Biosimilars of Rituximab Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst